Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04041843 · ClinicalTrials.gov registry record · Phase 2
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
A Phase 2 study of Venous Thromboembolism, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04041843: Completed Phase 2 study of Venous Thromboembolism, sponsored by New York Medical College.
NCT04041843 is a Phase 2 study of Venous Thromboembolism that has completed, run by New York Medical College. The registered enrollment target is 25 participants, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04041843, a Phase 2 study of Venous Thromboembolism, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
Primary Outcome
No new VTE
Conditions Studied
Interventions
- DRUG Apixaban
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
What the finished NCT04041843 record still lists
NCT04041843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.
NCT04041843 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04041843 about?
NCT04041843 is a clinical study titled "Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism". Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
What is the current status of trial NCT04041843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-06-02. Estimated completion is 2022-05-31.
What conditions does trial NCT04041843 study?
This clinical trial studies the following conditions: Venous Thromboembolism.
What interventions are being tested in trial NCT04041843?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT04041843?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04041843 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04041843's enrollment target sits among peer trials
25 47th of 47 the lowest of 47 other Venous Thromboembolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
RECRUITING · Phase 2
-
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
ACTIVE NOT RECRUITING · Phase 2
-
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
COMPLETED · Phase 2
-
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
COMPLETED · Phase 2
-
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI